柳氮磺胺吡啶在溃疡性结肠炎中的代谢。I. 住院患者中代谢产物与治疗反应的关系
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
作者信息
Das K M, Eastwood M A, McManus J P, Sircus W
出版信息
Gut. 1973 Aug;14(8):631-41. doi: 10.1136/gut.14.8.631.
Abstract
The metabolism of salicylazosulphapyridine was studied in 16 patients with ulcerative colitis admitted to hospital. The acetylator phenotype was determined on admission. The mean serum concentration (mug/ml) (at steady state eight +/- two days in patients responding to treatment) of SASP, total SP, and 5-ASA were 18.7 +/- 12.8; 53.7 +/- 23.1; and 1 +/- 0.9 for slow acetylators and 17.6 +/- 7.1; 31 +/- 9.0 and 1 +/- 0.9 for fast acetylators respectively. Twenty-four hour urinary excretion of SASP, total SP, and 5-ASA were 4.6% +/- 3.1; 52% +/- 9.6 and 22.3 +/- 6.7% of the administered dose respectively. Serum total SP concentration of 20 to 50 mug/ml appeared to coincide with clinical improvement in the absence of any side effects related to salicylazosulphapyridine. No such relationship could be shown with serum SASP, individual metabolites, or 5-aminosalicyclic acid.
摘要
对16例入院的溃疡性结肠炎患者的柳氮磺胺吡啶代谢情况进行了研究。入院时测定乙酰化表型。慢乙酰化者的柳氮磺胺吡啶（SASP）、总磺胺吡啶（SP）和5-氨基水杨酸（5-ASA）的平均血清浓度（μg/ml）（在对治疗有反应的患者中，稳态时为8±2天）分别为18.7±12.8；53.7±23.1；和1±0.9，快乙酰化者分别为17.6±7.1；31±9.0和1±0.9。SASP、总SP和5-ASA的24小时尿排泄量分别为给药剂量的4.6%±3.1；52%±9.6和22.3±6.7%。血清总SP浓度在20至50μg/ml时，在无任何与柳氮磺胺吡啶相关的副作用的情况下，似乎与临床改善相符。血清SASP、单个代谢物或5-氨基水杨酸之间未显示出这种关系。
相似文献
1
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢。I. 住院患者中代谢产物与治疗反应的关系
Gut. 1973 Aug;14(8):631-41. doi: 10.1136/gut.14.8.631.
2
Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Scand J Gastroenterol. 1986 Aug;21(6):693-700. doi: 10.3109/00365528609011102.
3
The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢：II 门诊患者中代谢物与疾病进展的关系研究。
Gut. 1973 Aug;14(8):637-41. doi: 10.1136/gut.14.8.637.
4
Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
Pediatr Pharmacol (New York). 1982;2(4):323-33.
5
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）在人体中的处置与代谢。
Br J Clin Pharmacol. 1982 Apr;13(4):523-8. doi: 10.1111/j.1365-2125.1982.tb01415.x.
6
The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.乙酰化表型对柳氮磺胺吡啶在人体内代谢的影响。
J Med Genet. 1983 Feb;20(1):30-6. doi: 10.1136/jmg.20.1.30.
7
Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.柳氮磺胺吡啶与丙烯酸包衣5-氨基水杨酸在正常受试者和结肠炎患者中的吸收与代谢比较。
Br J Clin Pharmacol. 1984 Apr;17(4):474-6. doi: 10.1111/j.1365-2125.1984.tb02375.x.
8
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).肠道转运时间对柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）偶氮还原的影响。
Gut. 1979 Apr;20(4):300-4. doi: 10.1136/gut.20.4.300.
9
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
10
Different therapy for different types of ulcerative colitis in China.中国针对不同类型溃疡性结肠炎的不同治疗方法。
World J Gastroenterol. 2004 May 15;10(10):1513-20. doi: 10.3748/wjg.v10.i10.1513.
引用本文的文献
1
Bioavailability Based on the Gut Microbiota: a New Perspective.基于肠道菌群的生物利用度：一个新视角。
Microbiol Mol Biol Rev. 2020 Apr 29;84(2). doi: 10.1128/MMBR.00072-19. Print 2020 May 20.
2
Infectious Agents and Inflammation: The Role of Microbiota in Autoimmune Arthritis.感染因子与炎症：微生物群在自身免疫性关节炎中的作用
Front Microbiol. 2018 Jan 16;8:2696. doi: 10.3389/fmicb.2017.02696. eCollection 2017.
3
5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.5-氨基水杨酸通过对肠道过氧化物酶体增殖物激活受体γ（PPARγ）和过氧化物酶体增殖物激活受体α（PPARα）的双重作用，改善高脂高胆固醇饮食喂养小鼠的血脂谱。
PLoS One. 2018 Jan 19;13(1):e0191485. doi: 10.1371/journal.pone.0191485. eCollection 2018.
4
Microbiota and chronic inflammatory arthritis: an interwoven link.微生物群与慢性炎症性关节炎：一个相互交织的联系。
J Transl Med. 2016 Aug 4;14(1):233. doi: 10.1186/s12967-016-0989-3.
5
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?用于治疗溃疡性结肠炎的美沙拉嗪制剂：它们都一样吗？
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):137-44. doi: 10.4292/wjgpt.v6.i4.137.
6
Penta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways.五-O-没食子酰基-β-D-葡萄糖通过抑制MyD88/NF-κB和MyD88/MAPK信号通路减轻炎症。
Br J Pharmacol. 2013 Nov;170(5):1078-91. doi: 10.1111/bph.12333.
7
Medical management of Crohn's disease.克罗恩病的药物治疗
Clin Colon Rectal Surg. 2007 Nov;20(4):269-81. doi: 10.1055/s-2007-991026.
8
Medical treatment of ulcerative colitis.溃疡性结肠炎的医学治疗。
Clin Colon Rectal Surg. 2004 Feb;17(1):7-19. doi: 10.1055/s-2004-823066.
9
The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢：II 门诊患者中代谢物与疾病进展的关系研究。
Gut. 1973 Aug;14(8):637-41. doi: 10.1136/gut.14.8.637.
10
N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.N-乙酰转移酶2慢乙酰化基因型与柳氮磺胺吡啶治疗炎症性肠病的不良反应相关。
Can J Gastroenterol. 2007 Mar;21(3):155-8. doi: 10.1155/2007/976804.
本文引用的文献
1
PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.泼尼松作为溃疡性结肠炎缓解期的维持治疗药物。
Lancet. 1965 Jan 23;1(7378):188-9. doi: 10.1016/s0140-6736(65)90973-6.
2
CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.柳氮磺胺吡啶治疗溃疡性结肠炎的对照试验
Gut. 1964 Oct;5(5):437-42. doi: 10.1136/gut.5.5.437.
3
Distribution and metabolism of salicyl-azo-sulfapyridine. II. A study with S35-salicyl-azo-sulfapyridine and S35-sulfapyridine.柳氮磺胺吡啶的分布与代谢。II. 用S35-柳氮磺胺吡啶和S35-磺胺吡啶进行的一项研究。
Acta Med Scand. 1963 Apr;173:391-9. doi: 10.1111/j.0954-6820.1963.tb17422.x.
4
Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.柳氮磺胺吡啶和水杨酸偶氮磺胺嘧啶治疗溃疡性结肠炎
Lancet. 1962 May 26;1(7239):1094-6. doi: 10.1016/s0140-6736(62)92080-9.
5
An improved and simplified method of detecting the acetylator phenotype.一种检测乙酰化酶表型的改良简化方法。
J Med Genet. 1969 Dec;6(4):405-7. doi: 10.1136/jmg.6.4.405.
6
Ulcerative colitis. A clinical study of 399 patients.溃疡性结肠炎。399例患者的临床研究。
J R Coll Surg Edinb. 1971 Nov;16(6):338-51.
7
The polymorphic acetylation of sulphapyridine in man.人磺胺吡啶的多态性乙酰化作用。
J Med Genet. 1972 Jun;9(2):168-71. doi: 10.1136/jmg.9.2.168.
8
Salazopyrin metabolism in ulcerative colitis.
Gut. 1972 Oct;13(10):840.
9
Absorption, metabolism, and excretion of salicylazosulfapyridine in man.柳氮磺胺吡啶在人体中的吸收、代谢及排泄
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539-51. doi: 10.1002/cpt1972134539.
10
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.健康受试者中乙酰化代谢表型与柳氮磺胺吡啶的不良反应
Gut. 1972 Apr;13(4):278-84. doi: 10.1136/gut.13.4.278.
Zotero 插件